Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens.
Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein[3].
Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration[1]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y[2].
利福平是一种对细菌病原体具有强大和广谱抗生素作用的药物。
利福平（100 mg/mL）可阻断P-糖蛋白的功能活性。利福平不是P-糖蛋白的底物。利福平耐药机制与P-糖蛋白的功能活性无关[3]。
利福平（200，400 mg/kg）可以诱导高浓度脂肪肝[1]。利福平（30 mg/kg，i.p.）处理S464P生物膜后，这些导管中的生物荧光信号略有下降，但比父母信号更早地重新绑定，而利福平对感染突变体H481Y的小鼠的生物荧光信号没有影响[2]。
References:
[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7.
[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2.
[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61.